Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC), associated with aggressive disease course, refractoriness to chemotherapy, and poor survival. Excellent response of PSC to immune checkpoint inhibitors were reported in small case reports/series, but it remains unclear whether PSC is still associated with poor prognosis compared to other NSCLC when treated with immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.